Glaxo not seeking re-hearing in Ellipta litigation, says Vectura

(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.
As a result, the Court of Appeals has issued the Mandate to the US District Court for the District of Delaware and Vectura said it expects Glaxo to make payment of the current award plus interest by late January 2021.

The specific amount of the award will be confirmed in due course, Vectura said.

Vectura filed a complaint in the US back in 2016 alleging that Glaxo's Ellipta inhalers infringed one of its patents. Last month, GlaxoSmithKline lost an appeal seeking to overturn an $89.7m verdict handed down by a jury after finding that the company's Ellipta line of inhalers did indeed infringe a patent belonging to Vectura.